Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA Names Stephen J. Ubl as Next President and CEO; Succeeds John Castellani

Steve UblWashington, DC, September 29, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) Board of Directors on Friday announced that Stephen J. Ubl will be the next president and chief executive officer (CEO) of the association.

Ubl joins PhRMA after more than ten years as the president and CEO of the Advanced Medical Technology Association (AdvaMed), the world’s largest medical technology association.

He succeeds John J. Castellani who announced earlier this year that he will be retiring at the end of the year.

Ubl is a recognized leader in health care advocacy and public policy.  During his tenure at AdvaMed, important reforms were passed related to the U.S. Food and Drug Administration review process and Medicare’s coverage and reimbursement of medical technologies.

He is routinely named as one of Washington’s most effective advocates by Washington political publications and has appeared on Modern Healthcare’s list of 100 Most Influential People in Healthcare.

“Steve’s extensive experience, depth of knowledge and patient-centered approach to advocacy will serve him well in leading the association at a time when our industry is bringing tremendous medical innovation to patients, the health care system and society,” said Kenneth C. Frazier, chairman and CEO of Merck & Co., Inc., and chairman of the PhRMA Board of Directors.

Ubl has a long track record of working collaboratively with a broad array of health care stakeholders, including patient advocacy organizations, providers and public and private payers.

He was a longstanding board member of the National Health Council, a leading umbrella organization for voluntary health care organizations, and has been personally involved with JDRF and LUNGevity, the largest national lung cancer-focused nonprofit.

“This is an exciting time to be joining the biopharmaceutical industry as new medicines are coming to the market that are completely transforming care for patients fighting cancer, heart disease, hepatitis c and other debilitating diseases,” said Ubl.

“I look forward to working with PhRMA member companies and the broader health care advocacy community to advance public policies that will improve patients’ access to medicines and foster the continued development of new treatments and cures for patients,” Ubl continued.

Ubl first joined AdvaMed in 1998 as executive vice president of federal government relations. He left the organization in 2004 to open his own health care consulting firm, serving top health care companies.

In July 2005, Ubl was chosen to lead AdvaMed as president and CEO. Prior to AdvaMed, Ubl was vice president of legislation for the Federation of American Hospitals.

Ubl began his Washington career on Capitol Hill, where he worked for U.S. Senator Charles E. Grassley (R-Iowa).

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.  Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.